LeonaBio

LeonaBio Financial Leverage

The Financial Leverage (Equity Multiplier) of LeonaBio (LONA) as of Oct 29, 2026 is 3.32. In the previous year, Financial Leverage (Equity Multiplier) was 1.31 — a change of 152.97% (higher).

Financial Leverage

3.32

YoY

152.97%

Last updated:

Financial Leverage (Equity Multiplier) of LeonaBio is 2025 3.32 . Financial Leverage (Equity Multiplier) of LeonaBio was 2024 1.31 . It decreases by 152.97% higher compared to the previous year.

The LeonaBio Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-0.33 USD
Jan 1, 2019
-0.11 USD
Jan 1, 2020
1.02 USD
Jan 1, 2021
1.03 USD
Jan 1, 2022
1.10 USD
Jan 1, 2023
1.23 USD
Jan 1, 2024
1.31 USD
Jan 1, 2025
3.32 USD
The LeonaBio Financial Leverage history
YEARFinancial LeverageYoY
3.32+152.97%
1.31+6.50%
1.23+12.11%
1.10+6.18%
1.03+1.45%
1.02-1,018.35%
-0.11-66.51%
-0.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Financial Leverage (Equity Multiplier) of LeonaBio is 3.32 in 2025.

Financial Leverage (Equity Multiplier) of LeonaBio changed from 1.31 to 3.32, representing a 152.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LeonaBio

All Key Metrics — LeonaBio